April 2nd 2023
The company also recently announced updates in the MATRICS-1 clinical trial for hemorrhagic trauma.
AMP-101 Shows Pharmacologic and Safety Promise for Neuromuscular Disorders in Preclinical Study
The Amplo Biotechnology gene therapy showed positive findings in mouse models, suggestive of the therapy’s development for use in a clinical setting. The AAV therapy delivers DOK7 gene, which has shown benefit in neuromuscular disorders.
Sarepta’s SRP-9001 Shows Functional Improvements in DMD Integrated Analysis
Presented at MDA 2023, the gene therapy (also known as delandistrogene moxeparvovec) showed significant improvements on NSAA total score, 10-meter walk/run scores, and time to rise scores relative to an external control cohort.